De Monitor - Pharming Professor schreef op 4 april 2021 13:02:
[...]
Verkondigde?
Je doelt op de uitspraak tijdens de analistenbijeenkomst?
I would say that this is
purely speculative here, that in the third quarter, there
could be
some reporting from these -- from
either one of these trials. And
I'm not sure at this point in time which trial will actually be able to report first. Because our U.S. trials also -- our own trial is also very active and has a different longer -- lower dose per day, but a longer duration of treatment. And we're -- but yes, so the third quarter is
probably a reasonable
expectation that there
could be
some news from that.
Als je ziet hoe zelfverzekerd Pharming zich uitsprak over de zogenaamde veelbelovende pijplijn en dan in dit antwoord zoveel onzekerheid ziet zitten moet je wel erg naïef zijn om dan in Q3 resultaten te verwachten.